Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Bupivacaine Injection Leads to Muscle Force Reduction and Histologic Changes in a Murine Model

Full text
Author(s):
McNeill Ingham, Sheila Jean [1, 2] ; Pochini, Alberto de Castro [1, 3] ; de Oliveira, Daniel Antonio [1, 3] ; Garcia Lisboa, Bianca Cristina [4] ; Beutel, Abram [4] ; Valero-Lapchik, Valderez Bastos [4] ; Ferreira, Ana Maria [5] ; Abdalla, Rene Jorge [1, 3] ; Cohen, Moises [1, 3] ; Han, Sang Won [6, 4]
Total Authors: 10
Affiliation:
[1] Univ Fed Sao Paulo, Dept Orthopaed Surg, Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Dept Phys Med & Rehabil, Sao Paulo - Brazil
[3] Univ Fed Sao Paulo, Ctr Sports Med, Sao Paulo - Brazil
[4] Univ Fed Sao Paulo, Ctr Gene Therapy, Sao Paulo - Brazil
[5] Univ Fed Fluminense, Ctr Med Sci, Sch Vet, Rio De Janeiro - Brazil
[6] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo - Brazil
Total Affiliations: 6
Document type: Journal article
Source: PM&R; v. 3, n. 12, p. 1106-1109, DEC 2011.
Web of Science Citations: 7
Abstract

Objective: To evaluate the effect of bupivacaine on muscle force and histology. We hypothesize that bupivacaine will worsen the muscle's physiological activity. Setting: Controlled laboratory experiment. Methods: Bupivacaine (0.5 mL, 0.5%) was injected into the mid belly and distal portions of the right gastrocnemius in 32 Wistar male rats (the left gastrocnemius was used as a control). After 5, 14, 21, and 28 days, in groups of 4, muscle force was evaluated and the animals were euthanized by an overdose of anesthetic for histologic evaluation. One-way analysis of variance was used to analyze data from force and weight measurements. Only the values of P < .05 were considered to be statistically significant. Results: Bupivacaine causes a process of degeneration-regeneration of the muscle fibers and it also causes a reduction in muscle force, which is significant at 2 and 3 weeks and does not normalize at 4 weeks. The muscle injury is obvious after 5 days, and the degenerative process is predominant at 2 and 3 weeks. We found an increase in muscle mass in the acute phase and a decrease in muscle force. Conclusion: Although our results do not allow a direct clinical application, we believe that caution should be warranted when intramuscular bupivacaine is used. PM R 2011;3:1106-1109 (AU)

FAPESP's process: 11/00859-6 - Role of GM-CSF in the repair of muscule injury: gene therapy for muscle injuries
Grantee:Sang Won Han
Support Opportunities: Regular Research Grants